期刊文献+

P-gp在结直肠癌中的表达及临床意义 被引量:2

Expression and significance of P-gp in colorectal carcinioma
暂未订购
导出
摘要 目的检测结直肠癌P-gp的表达,探讨其临床意义。方法采用免疫组织化学MaxVisionTM二步法,检测结直肠癌标本78份,癌旁正常肠组织31份。结果P-gp表达阳性率为83.3%(65/78),与癌周正常组织比较差异有统计学意义(P<0.05),其表达与浸润深度有关,差异有统计学意义(P<0.05),与性别、年龄、临床分期、淋巴结转移无关,差异无统计学意义(P>0.05)。结论P-gp在结直肠癌的原发耐药上起着重要作用,检测P-gp的表达对大肠癌的化疗药物和方案选择具有参考意义。 Objective To study the expression and clinical significance of P-gp in colorectal carcinoma. Methods Immunohisto- chemistry was used to examine the P-gp expression in 78 cases of colorectal carcinoma and 31 cases of normal tissues. Results The positive expression of P-gp in colorectal carcinoma was 83.3% (65/78) ,higher than that in normal tissue(P〈0.05). The expres- sion of P-gp was related to the degree of invasion(P〈0.05),but not related to sex, age, clinical staging and nodal metastasis(P〉 0.05). Conclusion P-gp play important roles in the primary multidrug resistance of colorectal carcinoma. Detecting the expression of P-gp in colorectal carcinoma has the referential significance with regard to the choice of drugs and plan in colorectal carcinoma chemotherapy.
出处 《重庆医学》 CAS CSCD 北大核心 2009年第20期2580-2581,共2页 Chongqing medicine
关键词 结直肠癌 P-GP 免疫组织化学 colorectal carcinoma p-glycoproteins immunohistochemistry
  • 相关文献

参考文献5

  • 1蒋业贵,王宇明,刘同华.肿瘤耐药相关标志在肝细胞癌中的表达及其意义[J].重庆医学,2006,35(1):47-48. 被引量:7
  • 2Chang G. Multidrug resistance ABC transporters [J]. FEBS Letters, 2003,555 ( 1 ) : 102.
  • 3Ricardo PT. Multidrug resistance retrospect and prospects in anti-cancer drug treatment [J]. Current Medicinal Chemistry, 2006,33 : 1859.
  • 4Gregory D,Fojo T. The role of ABC transporters in clinical praclice[J]. The Oncologist, 2003,8 : 411.
  • 5Stein WD, Bates SE, Fojo T. Intractable cancer: The many faces of multidrug resistance and the many targets it presents for therapeutic attack[J]. Current Drug Targets, 2004,5:333.

二级参考文献11

  • 1Raaijmakers HG, Izquierdo MA, Lokhorst HM, et al,Lung-resistance-related protein expression is a negative predictive factor for response to conventional low but not to intensified dose alkylating chemotherapy in multiple myeloma [J]. Blood, 1998, 91(3): 1029.
  • 2Barnouin K, Leier I, Jedlitschky G, et al. Multidrug resistance protein-mediated transport of chlorambucil and melphalan conjugated to glutathione [J]. Br J Cancer,1998, 77(2): 201.
  • 3Sood AK, Buller RE. Drug resistance in ovarian cancer:germ the laboratory to the clinic [J]. Obstet Gynecol,1998, 92(2): 312.
  • 4Ng IO, Liu CL, Fan ST, et al. Expression of P-glycoprotein in hepatocellular carcinoma. A determinant of chemotherapy response[J]. Am J Clin Pathol, 2000, 113(3): 355.
  • 5den Boer ML, Pieters R, Kazemier KM, et al. Relationship between major vault protein/lung resistance protein,multidrug resistance-associated protein, P-glyeoprotein expression, and drug resistance in childhood leukemia[J]. Blood , 1998, 91(6): 2092.
  • 6Sharp SY, Smith V, Hobbs S, et al. Lack of a role for MRP1 in platinum drug resistance in human ovarian cancer cell lines [J]. Br J Cancer, 1998, 78(2): 175.
  • 7邹伟,张昭成,李慎谦,牛兆山,李玉军.胎盘型谷胱甘肽S-转移酶在人肝癌及癌旁组织的表达[J].青岛医学院学报,1998,34(1):8-9. 被引量:2
  • 8曹利平,彭淑牖,林敏,林汉庭.糖蛋白在胆囊良恶性肿瘤中的表达[J].中华肿瘤杂志,1999,21(2):119-121. 被引量:7
  • 9李立人,施公胜,张弘,刘艳华,孟宪镛.谷胱甘肽S-转移酶及同工酶在原发性肝癌中的表达[J].南通医学院学报,1999,19(2):149-151. 被引量:3
  • 10陈锡美,刘文滨,李春海.食管癌活检标本多药耐药基因表达及意义[J].中华消化杂志,2000,20(1):40-41. 被引量:7

共引文献6

同被引文献45

  • 1立彦,王自正.Pgp介导的肿瘤多药耐药逆转研究进展(文献综述)[J].放射免疫学杂志,2005,18(2):133-134. 被引量:14
  • 2Takara K, Sakaeda T, Okumura K. An update on overcoming MDRl-mediated multidrug resistance in cancer chemotherapy [J]. Curr Pharm Des, 2006, 12: 273-286.
  • 3Hirose M. The process behind the expression of mdr-1/P-gp an imp/ MRP in human leukemia/lymphoma [J]. Anticancer Res, 2009, 29 (4): 1073-1077.
  • 4Breier A, Baraneik M, Sulova Z, et al. P-glycoprotein im-plications of metabolism of neoplastic cells and cancer therapy [J]. Curr Cancer Drug Targets, 2005, 5 (6) :457-468.
  • 5Nakajima M, Fujiki Y, Kyo S, et al. Pharmacokineties of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1 [J]. J Clin Pharmacol, 2005, 45(6): 674-682.
  • 6Buda G, Orciuolo E, Maggini V, et al. MDR1 modulates apop tosis in CD34^+ leukemic cells [J]. Ann Hematol, 2008, 87 (12) : 1017- 1018.
  • 7Bergman AM, Pinedo HiM, Talianidis I, et al. Increased sensitivity to gemcitabine of Pglycoprotein and multi-drug ed proteinoverexpressing human cancer cell lines [J]. Br J Cancer, 2003, 88:1963-1970.
  • 8Baumert C, Hilgeroth A. Recent advances in the development ofP-gp inhibitors [J]. Anticancer Agents Med Chem, 2009, 9(4): 415-436.
  • 9Wang Q, Strab R, Kardos P, et al. Application and limitation of in-hibitors in drug-transporter interactions studies [J]. Int J Pharrn, 2008, 356(1-2):12-18.
  • 10Balimane PV, Marino A, Chong S. P-gp Inhibition potential in cell-based models:which "calculation" method is the most accurate? [J]. AAPS J, 2008, 10: 577-586.

引证文献2

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部